These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Liu D; Liu X; Xing M Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969 [TBL] [Abstract][Full Text] [Related]
23. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells. Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584 [TBL] [Abstract][Full Text] [Related]
24. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related]
25. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Welsh SJ; Rizos H; Scolyer RA; Long GV Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329 [TBL] [Abstract][Full Text] [Related]
26. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Carlino MS; Long GV; Kefford RF; Rizos H Crit Rev Oncol Hematol; 2015 Dec; 96(3):385-98. PubMed ID: 26358420 [TBL] [Abstract][Full Text] [Related]
27. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
28. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
29. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679 [TBL] [Abstract][Full Text] [Related]